Publicacións en colaboración con investigadores/as de Mutua de Terrassa (12)

2024

  1. Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI)

    American Journal of Hematology

  2. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

2023

  1. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

    Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

2022

  1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  2. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

2021

  1. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

  2. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

    Annals of Hematology, Vol. 100, Núm. 7, pp. 1769-1778

2020

  1. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols

    European Journal of Haematology, Vol. 105, Núm. 2, pp. 138-147

2019

  1. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

  2. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

    Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330

2017

  1. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

    Blood

2014

  1. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial

    The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111